Open access · CC-BY
via OpenAlex
Proteostasis breakdown and aggregate diversity in aging and neurodegenerative disease
Frontiers in Aging Neuroscience · 2026
Abstract
Protein aggregation and proteostasis(definition) decline are central features of aging and neurodegenerative disease, arising from progressive impairment of protein quality-control systems and transitions into aggregation-prone states. During aging, diverse proteins, including metabolic and proteostasis-related factors, gradually accumulate in aggregated forms as proteostasis capacity declines. Although these aggregates often remain compatible with cellular function, increasing aggregate burden progressively challenges proteostasis resilience. Neurodegenerative diseases are characterized by the emergence and amplification of highly toxic, structurally ordered protein assemblies, including amyloid-β (Aβ) and tau, which exist along a continuum with broader age-associated proteome instability rather than as entirely distinct phenomena. Oxidative and metabolic imbalances promote non-enzymatic post-translational modifications (PTMs), including cysteine oxidation, S-nitrosylation, and carbonylation, which alter protein structure, impair degradation pathways, and facilitate misfolding and aggregation. Here, we compare oxidative PTM-driven aggregates observed during aging with disease-associated protein assemblies, highlighting both shared biophysical mechanisms and distinct pathological outcomes. We propose a threshold model in which the cumulative burden of oxidative PTMs, protein misfolding, and impaired clearance progressively erodes proteostasis capacity, increasing susceptibility to the emergence of selective, self-amplifying aggregates. By integrating intracellular quality-control systems with extracellular clearance pathways, including glymphatic and meningeal lymphatic networks, this framework provides a mechanistic perspective on how aggregate diversity evolves toward disease-associated pathology and suggests therapeutic strategies that combine aggregate-specific targeting with restoration of global proteostasis and clearance capacity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fnagi.2026.1910154
- Canonical
- link ↗
- Fetched
- 2026-10-04 MST
Cite this
APA
Khan, Z.N. (2026). Proteostasis breakdown and aggregate diversity in aging and neurodegenerative disease. <em>Frontiers in Aging Neuroscience</em>. https://doi.org/10.3389/fnagi.2026.1910154
Vancouver
Khan ZN. Proteostasis breakdown and aggregate diversity in aging and neurodegenerative disease. Frontiers in Aging Neuroscience. 2026. doi:10.3389/fnagi.2026.1910154.
BibTeX
@article{zohaib2026Proteo,
title = {Proteostasis breakdown and aggregate diversity in aging and neurodegenerative disease},
author = {Zohaib N. Khan},
journal = {Frontiers in Aging Neuroscience},
year = {2026},
doi = {10.3389/fnagi.2026.1910154},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in aging neuroscience 2026
Open access · OA
Proteostasis breakdown and aggregate diversity in aging and neurodegenerative disease.
Translational Neurodegeneration 2026
Open access · CC-BY
Brain clearance of protein aggregates in degenerative diseases: the role of microglia and astrocytes
Preprints.org 2025
Preprint · CC-BY
Protein Aggregation and Proteostasis Failure in Neurodegenerative Diseases: Mechanisms, Structural Insights, and Therapeutic Strategies
Frontiers in Neurology 2021
Open access · CC-BY
Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation
PLoS Biology 2023
Open access · CC-BY
A safety mechanism enables tissue-specific resistance to protein aggregation during aging in C. elegans
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · CC-BY